Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. The approval of all resolutions underscores strong shareholder support for the company’s strategic direction and recent initiatives.
Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth. The listing of Veraxa Biotech on a major U.S. exchange is expected to enhance visibility and access to capital markets, benefiting Xlife Sciences as a significant shareholder.
The company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences’ portfolio companies. Management said the platform will integrate academic research with commercial development and serve as a cornerstone of the company’s future innovation pipeline, while also outlining upcoming capital markets activities. This platform could streamline the transition from research to commercial-stage products, potentially reducing time-to-market for new therapies.
Xlife Sciences operates as an incubator and accelerator focused on value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector. The company aims to provide solutions for high unmet medical needs and improve quality of life by bridging research and development to healthcare markets. It carefully selects projects in four areas: technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health, and participates in their subsequent performance.
For more information about Xlife Sciences, visit www.xlifesciences.ch. The full press release is available at https://ibn.fm/nfUvM.
